Novel Antibacterial Compounds Targeting Penicillin-Binding Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial compounds are ineffective against a wide range of bacterial strains, particularly those resistant to beta-lactam antibiotics, and lack specificity in targeting bacterial cell wall synthesis, leading to potential toxicity and resistance issues.
Innovation Solution
Development of novel antibacterial compounds that target penicillin-binding proteins (PBPs) using specific chemical structures, such as 1,2,4-oxadiazoles, which inhibit bacterial cell wall synthesis without affecting mammalian cells, thereby providing selective toxicity and broad-spectrum activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-lactam antibiotics are used to inhibit PBPs, then bacterial cell wall synthesis is inhibited, but bacterial resistance develops and toxicity to mammalian cells occurs
Solution Approach 1:
The patent modifies the chemical structure of PBP inhibitors by changing parameters such as introducing fluorinated aromatic rings, modifying side chains, and adjusting molecular weight to optimize binding affinity while reducing toxicity. This allows differentiation between bacterial and mammalian cell interactions.
Solution Approach 2:
The invention introduces specific functional groups at particular locations in the molecular structure to enhance binding to bacterial PBPs while avoiding interaction with mammalian cells. The local chemical properties are optimized for selective toxicity.
2Adaptability or versatility
If broad-spectrum antibacterial compounds are developed, then activity against multiple bacterial strains is achieved, but specificity in targeting bacterial cell wall synthesis is lost
Solution Approach 1:
The patent designs compounds that can inhibit multiple PBP enzymes across different bacterial species, achieving broad-spectrum activity. The molecular structure is optimized to bind with varying affinities to different PBP types, providing versatility while maintaining mechanism-specificity.
3Reliability
If existing antibacterial compounds are used, then treatment is provided, but minimum inhibitory concentrations are not optimized, leading to resistance
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types, molecular size, and functional group positions to optimize the minimum inhibitory concentration. This reduces the dosage required and minimizes selective pressure for resistance.
Data Source
AI summary
Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.